Viral G Protein–Coupled Receptors: Attractive Targets for Herpesvirus-Associated Diseases

Timo W. M. De Groof,1 Elizabeth G. Elder,1 Marco Siderius, 2 Raimond Heukers, John H. Sinclair, and Martine J. Smit

In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium (T.W.M.D.G.); Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom (E.G.E., J.H.S.); Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (M.S., R.H., M.J.S.); and QVQ Holding B.V., Utrecht, The Netherlands (R.H.)

Abstract
Herpesviruses are ubiquitous pathogens that establish lifelong, latent infections in their host. Spontaneous reactivation of herpesviruses is often asymptomatic or clinically manageable in healthy individuals, but reactivation events in immunocompromised or immunosuppressed individuals can lead to severe morbidity and mortality. Moreover, herpesvirus infections have been associated with multiple proliferative cardiovascular and post-transplant diseases. Herpesviruses encode viral G protein–coupled receptors (vGPCRs) that alter the host cell by hijacking cellular pathways and play important roles in the viral life cycle and these different disease settings. In this review, we discuss the pharmacological and signaling properties of these vGPCRs, their role in the viral life cycle, and their contribution in different diseases. Because of their prominent role, vGPCRs have emerged as promising drug targets, and the potential

Address correspondence to: Prof. Dr. Martine J. Smit, Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands. E-mail: mj.smit@vu.nl

This work was supported by the Netherlands Organization for Scientific Research (NWO) [Vici Grant 016.140.657].
No author has an actual or perceived conflict of interest with the contents of this article.

1T.W.M.D.G. and E.G.E. contributed equally to this work.
https://doi.org/10.1124/pharmrev.120.000186.
of vGPCR-targeting therapeutics is being explored. Overall, these vGPCRs can be considered as attractive targets moving forward in the development of antiviral, cancer, and/or cardiovascular disease treatments.

**Significance Statement**—In the last decade, herpesvirus-encoded G protein–coupled receptors (GPCRs) have emerged as interesting drug targets with the growing understanding of their critical role in the viral life cycle and in different disease settings. This review presents the pharmacological properties of these viral receptors, their role in the viral life cycle and different diseases, and the emergence of therapeutics targeting viral GPCRs.

### I. Family of Viral G Protein–Coupled Receptors

#### A. Herpesvirus-Encoded G Protein–Coupled Receptors

Herpesviruses are ubiquitous pathogens that establish lifelong, latent infections in their host (Vischer et al., 2006; Reid et al., 2016). One can distinguish three families of herpesviruses: α-, γ-, and β-herpesviruses, also referred to as HHV-1 to HHV-8. For β- and γ-herpesviruses, infections are usually mild or asymptomatic in healthy individuals. However, spontaneous reactivation in immunonaiive, immunocompromised, or immunosuppressed individuals, such as neonates, transplant patients, and patients with AIDS, can lead to severe morbidity and mortality (Vischer et al., 2014; Reid et al., 2016). Moreover, herpesvirus infections have been associated with multiple inflammatory, cardiovascular, and onco logical diseases (Vischer et al., 2014).

One key class of proteins involved in viral pathogenesis is the family of G protein–coupled receptors (GPCRs). GPCRs are a superfamily of receptors involved in a wide variety of cellular processes (Rosenbaum et al., 2009; Kobilka, 2013). Because of their regulatory role, human GPCRs are involved in multiple diseases and are among the most important drug targets (Hauser et al., 2017). Chemokine receptors are a subclass of GPCRs that play a pivotal role in both regulation of the immune system and tumorigenesis (Murdoch and Finn, 2000; Dorsam and Gutkind, 2007; Ransohoff, 2009; Mollica Poeta et al., 2019). Of these, CXCR4 and CCR5 serve as coreceptors that facilitate the entry of HIV-1 virus into CD4-positive T cells (Bleul et al., 1997). Intriguingly, multiple human β- and γ-herpesviruses encode one or more homologs of human chemokine receptors (Vischer et al., 2006). Most likely, these viral GPCRs (vGPCRs) have been acquired from the human genome and modified during evolution (Slinger et al., 2011). In the last decades, it has become clear that these vGPCRs alter the host cell by hijacking cellular pathways and play important roles in the viral life cycle. In this review, we will give a thorough overview of the GPCRs encoded by HHV-4 (also known as Epstein-Barr virus (EBV)), HHV-5 (also known as human cytomegalovirus (HCMV)), HHV-6/7 (roseoloviruses), and HHV-8 (also known as Kaposi sarcoma–associated herpesvirus (KSHV)). We will address their pharmacological and signaling properties, role in the viral life cycle, and contribution to different disease settings. Moreover, modulators of vGPCR signaling and their therapeutic potential will be discussed. Finally, we will give our view on questions to address and future challenges to face in the field of viral GPCRs.

#### B. Pharmacological Properties of Viral G Protein–Coupled Receptors

1. **Homology to Chemokine Receptors.** To date, genes encoding for vGPCRs have been found in the genome of all human β- and γ-herpesviruses but not in genomes of the α-herpesviruses [HHV-1/HHV-2 (known as herpes simplex virus), HHV-3 (known as Varicella zoster)] (Fig. 1) (Vischer et al., 2006). The γ-herpesviruses EBV and KSHV each encode one vGPCR: BILF1 (EBV) and ORF74 (KSHV). In contrast, HCMV encodes four vGPCRs (US27, US28, UL33, and UL78), whereas HHV-6 and HHV-7 encode two vGPCRs (US12 and U51). Interestingly, all these viral receptors share homology with human chemokine receptors, with US28 having the highest homology (35% with CX3CR1), whereas U51 (encoded by HHV-7) only shares 2% homology with CCR2 (Fig. 1) (de Munnik et al., 2015). Because of their homology with human chemokine receptors, multiple vGPCRs (US28, ORF74, U12, and U51 of both HHV-6 and HHV-7) bind human chemokines (Fig. 1). Similar to their human counterparts, most vGPCRs are able to bind multiple chemokines. HCMV-encoded US28 binds various chemokines from the CC family (including CCL2 and CCL5), CX3CL1, and the KSHV-encoded chemokine vCCL2 (Gao and Murphy, 1994; Kuhn et al., 1995; Kledal et al., 1997, 1998). In contrast, KSHV-encoded GPCR ORF74 binds chemokines from the CXC family. This is not surprising,
since ORF74 shares the highest homology with CXCR2 (27%) (Rosenkilde et al., 1999). However, ORF74 also binds CXCL4, CXCL10, CXCL12, CCL1, CCL5, and vCCL2, which are chemokines that do not bind to CXCR2 (Arvanitakis et al., 1997; Geras-Raaka et al., 1998; Gershengorn et al., 1998). Finally, U12 and U51 (from both HHV-6 and HHV-7) are able to bind a multitude of CCL chemokines, and HHV-6-encoded U51 also binds CX3CL1, XCL1, and vCCL2 (Isegawa et al., 1998; Milne et al., 2000; Nakano et al., 2003; Tadagaki et al., 2005; Catusse et al., 2008).

Similar to human chemokine receptors, the N terminus of these viral receptors is essential for ligand binding (Scholten et al., 2012). In 2015, the crystal structure of US28 in complex with CX3CL1 revealed the interaction of this ligand with the N terminus of the receptor (Burg et al., 2015). Moreover, sulfonation of the tyrosine at position 16 on the N terminus of US28 has been shown to be important for chemokine binding (Casarosa et al., 2005). However, although the N terminus is essential for chemokine binding in general, the various chemokines can interact differentially with the N terminus. Similar observations were seen for ORF74, in which sulfonation of two tyrosine residues on the N terminus was important for binding of CXCL1 but not CXCL10 (Feng et al., 2010). Besides interacting differentially with the receptors, different chemokines can also modulate receptor signaling in different manners, which we will discuss in more detail later on. Although multiple ligands have been found for the abovementioned receptors, no ligands for EBV-encoded BILF1 and HCMV-encoded US27, UL33, and UL78 have been reported to date, designating them as orphan GPCRs.

2. Chemokine Scavengers. Although promiscuous chemokine binding to these receptors influences their signaling properties, it has also been suggested that some of these vGPCRs could act as “chemokine

**Fig. 1.** Pharmacological properties of human herpesvirus-encoded GPCRs. Overview of the different viral GPCRs (colored GPCRs in the middle) encoded by the herpesviruses HCMV (HHV-5), HHV-6, HHV-7, EBV, or KSHV; their known ligands (top); and interacting G proteins (bottom). Their closest human chemokine homolog and the percentage of total homology are depicted. For each vGPCR, known signaling properties (constitutive or ligand-dependent) have been annotated.
scavengers” or “chemokine sinks” (Bodaghi et al., 1998). For instance, extracellular levels of CCL2 and CCL5 were lower in HCMV-infected fibroblasts compared with uninfected fibroblasts, which was the result of co-internalization of these chemokines with US28 (Michelson et al., 1997; Bodaghi et al., 1998; Billstrom et al., 1999). Interestingly, US28 is a constitutively internalizing receptor, with approximately 80% of the US28 receptor population residing in perinuclear vesicles, including endosomes, multivesicular bodies, and the viral assembly compartment (Fraile-Ramos et al., 2001; Mokros et al., 2002; Droese et al., 2004). US28-mediated chemokine scavenging could reduce chemokine levels and thus minimize attraction of immune cells to HCMV-infected cells. A similar immune evasion role was proposed for HHV-6-encoded U51 in which extracellular CCL5 concentrations were lowered upon U51 expression or HHV-6 infection (Milne et al., 2000; Catusse et al., 2008). However, these reduced CCL5 levels were a consequence of reduced CCL5 expression on a transcriptional level rather than chemokine scavenging.

3. Constitutively Active Receptors. Another interesting feature of the vGPCRs, and in contrast to most human GPCRs, is their ability to signal in a ligand-independent, constitutively active manner. Examples include US28, UL33, BILF1, ORF74, and HHV-6-encoded U51 (Vischer et al., 2014). Moreover, these vGPCRs signal constitutively by coupling promiscuously to several G proteins, such as Gαq, Gαi, Gαs, and Gα12/13 (Fig. 1). The different signaling pathways activated by the different vGPCRs will be discussed in more detail in section III Role of Viral G Protein–Coupled Receptors in Disease when discussing their roles in specific disease settings.

4. Heteromerization or Cross Talk with Human Chemokine Receptors. vGPCRs can also influence cellular signaling by modulating the signaling properties of human GPCRs. Positive or negative modulation of GPCRs can occur via direct association (by heterodimerization) or via indirect mechanisms such as cross talk of signaling pathways; scavenging of shared downstream signaling proteins; or transcriptional regulation of the GPCRs, ligands, or signaling proteins (El-Asmar et al., 2005; Sohy et al., 2007, 2009; Chabre et al., 2009; Prezeau et al., 2010). BILF1 can form heterodimers with multiple chemokine receptors from the CCR and CXCR family, including CCR9, CCR10, CXCR3, and CXCR4 (Vischer et al., 2008; Nijmeijer et al., 2010). Coexpression of BILF1 and CXCR4 leads to impaired CXCR4 signaling by inhibition of CXCL12 binding to CXCR4 (Nijmeijer et al., 2010). Coexpression of BILF1 and US28 leads to enhanced CCR1-mediated nuclear factor-κB (NF-κB) activation upon CCL5 binding (Bakker et al., 2004). This was dependent on constitutive US28 signaling and not CCL5 binding to US28. UL33 and UL78 are known to form heterodimers with CXCR4 and CCR5 and inhibit CCL5-mediated internalization of the CCR5 receptor (Tadagaki et al., 2012). Moreover, both receptors inhibited CCR5-mediated cell migration. However, although UL78 increases CCL5-mediated activation of CCR5, UL33 coexpression inhibits CCR5 activation upon CCL5 binding. Finally, all four HCMV-encoded GPCRs seem to influence CXCR4 signaling and expression. Coexpression of US27 and CXCR4 leads to enhanced CXCR4 expression and signaling (Arnolds et al., 2013; Boeck et al., 2018). UL33, UL78, and US28 expression, on the other hand, downregulate CXCR4 expression and signaling (Tadagaki et al., 2012; Frank et al., 2016). In the case of HHV-7, U12 and U51 have shown to potentiate CCL19- and CCL22-induced CXCR4 and CCR7 signaling (Tadagaki et al., 2007).

Thus, although the vGPCRs show high homology to human chemokine receptors, their pharmacological profile is very different because of their ability to bind a broad spectrum of chemokines, constitutive activity, and promiscuous G protein coupling. Via binding or scavenging human chemokines, or interacting directly with human chemokine receptors or indirectly with their downstream pathways, viral GPCRs are able to tap in and modulate the endogenous chemokine/chemokine receptor system in infected cells.

II. Viral G Protein–Coupled Receptors in a Viral Setting

It is becoming increasingly clear that vGPCRs play important roles in both the lytic and latent life cycles of the viruses (Arfelt et al., 2015; Krishna et al., 2018; Pontejo et al., 2018; Frank et al., 2019). Table 1 summarizes the roles that have been ascribed to vGPCRs in viral settings. For many of these, it is likely that future work in more elaborate models will be needed to gain further insight into the functions of these proteins.

Elucidating the function of vGPCRs in the viral life cycle can be challenging, as some functions are only revealed in particular cell types or in vivo studies. Such a cell-type specificity of vGPCR function is nicely exemplified by the HCMV chemokine receptor homolog US28 (Krishna et al., 2018). For example, although US28 is dispensable for the in vitro infection of fibroblasts, it enhances cell-to-cell spread in epithelial and smooth muscle cells (Vieira et al., 1998; Noriega et al., 2014; Humby and O’Connor, 2015; Lollinga et al., 2017). Many groups have found US28 to be essential for latency in in vitro cultures of primary hematopoietic stem cells or myeloid lineage cells, with several
TABLE 1
Overview of the role of vGPCRs in a viral setting

<table>
<thead>
<tr>
<th>vGPCR (Virus and Lytic Expression Kinetics)</th>
<th>Role in Lytic Infection</th>
<th>Role in Latent Infection</th>
<th>Role in Dissemination/Immune Evasion</th>
<th>Orthologs</th>
</tr>
</thead>
<tbody>
<tr>
<td>UL33 (HCMV late) (Davis-Poynter et al., 1997)</td>
<td>Dispensable (Margulies et al., 1996) but enhances spread in multistep growth analyses (van Senten et al., 2002a); constitutive signaling (Casasosa et al., 2003a)</td>
<td>Expression detected but no role established (Cheng et al., 2017)</td>
<td>Murine and rat models suggest roles in replication in salivary gland, latency, and dendritic cell trafficking (Frank et al., 2019)</td>
<td>Murine - M33 rat - R33</td>
</tr>
<tr>
<td>UL78 (HCMV early) (Wagner et al., 2012)</td>
<td>Dispensable (Michel et al., 2005) but important for entry into epithelial cells and replication in epithelial cells (O’Connor and Shenk, 2012)</td>
<td>Expression detected but no role established (Cheng et al., 2017)</td>
<td>Murine and rat models suggest importance in replication in specific cell types in vivo (Oliveira and Shenk, 2001; Kaptein et al., 2003)</td>
<td>Murine - M78 rat - R78</td>
</tr>
<tr>
<td>US27 (HCMV late) (Vieira et al., 1998; Chambers et al., 1999; Margulies and Gibson, 2007)</td>
<td>Important for extracellular spread (O’Connor and Shenk, 2011); promotion of cell growth and survival (Tu and Spencer, 2014)</td>
<td>Expression not detected (Cheng et al., 2017; Shnayder et al., 2018)</td>
<td>Highly conserved but in vivo role unclear (Stegman and Margulies, 2017; Frank et al., 2019)</td>
<td>Present in primate CMVs but not rodent CMVs (Alcendor et al., 2009)</td>
</tr>
<tr>
<td>US28 (HCMV early) (Vieira et al., 1998)</td>
<td>Dispensable (Vieira et al., 1998; Humby and O’Connor, 2015); enhances infection of epithelial cells and smooth muscle cells (Noriega et al., 2014; Lollinga et al., 2017); constitutive and ligand-induced signaling (Krishna et al., 2018)</td>
<td>Required for latency in vitro models (Humby and O’Connor, 2015; Krishna et al., 2017a; Zhu et al., 2018); required for reactivation in humanized mice (Crawford et al., 2019)</td>
<td>Induces cell migration and adhesion (Melnichuk et al., 2004; Vomaske et al., 2009; Hjorto et al., 2013; Wu and Miller, 2016; Farrell et al., 2018; Aslam et al., 2019); chemokine sink (Randolph-Habecker et al., 2002); myeloid differentiation (Zhu et al., 2018; Crawford et al., 2019)</td>
<td>Present in primate CMVs but not rodent CMVs (Alcendor et al., 2009); five rhesus CMV US28 homologs characterized</td>
</tr>
<tr>
<td>U12 (HHV-6A/B late) (Isegawa et al., 1998)</td>
<td>Ligand-induced signaling (Isegawa et al., 1998); likely dispensable for viral replication (Dominguez et al., 1999)</td>
<td>Unknown</td>
<td>Homologs not functionally characterized</td>
<td></td>
</tr>
<tr>
<td>U51 (HHV-6A/B early) (Menotti et al., 1999)</td>
<td>Enhances viral replication (Zhen et al., 2005)</td>
<td>Unknown</td>
<td>Leukocyte migration/immunomodulation (Cutusse et al., 2008)</td>
<td>Homologs not functionally characterized</td>
</tr>
<tr>
<td>U12 (HHV-7)</td>
<td>Ligand-induced signaling (Nakano et al., 2003; Tadagaki et al., 2005)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Homologs not functionally characterized</td>
</tr>
<tr>
<td>U51 (HHV-7)</td>
<td>Ligand-induced signaling (Tadagaki et al., 2005)</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Homologs not functionally characterized</td>
</tr>
<tr>
<td>BILF1 (EBV early)</td>
<td>Immune evasion (cell intrinsic and extrinsic) (Arfelt et al., 2015; Morales-Sánchez and Fuentes-Panana, 2018)</td>
<td>Expressed at low levels (Tierney et al., 2015)</td>
<td>Likely immune evasion including evasion of cytotoxic T-cell recognition</td>
<td>BILF1 homologs characterized in primate lymphocryptoviruses (Spiess et al., 2015a)</td>
</tr>
<tr>
<td>ORF74 (KSHV early) (Chiou et al., 2002)</td>
<td>Necessary for efficient lytic replication (Sandford et al., 2009)</td>
<td>Expression kept at low levels (Vischer et al., 2014); possible reactivation from latency (Chen et al., 2009; Sandford et al., 2009)</td>
<td>Murine models indicate important roles in reactivation from latency (Moorman et al., 2003; López-Rodriguez et al., 2019)</td>
<td>MHV68 ORF74 (Virgin et al., 1997)</td>
</tr>
</tbody>
</table>

Mechanistic studies additionally identifying US28 signaling or ligand binding as contributory factors to latency establishment and/or maintenance (Humby and O’Connor, 2015; Krishna et al., 2017a, 2019, 2020; Zhu et al., 2018; Crawford et al., 2019; Elder et al., 2019). Potential roles for US28 in vivo have been postulated, including smooth muscle cell and myeloid cell migration (Waldhoer et al., 2002; Melnychuk et al., 2004; Vomaske et al., 2009), adhesion to endothelial cells (Wu and Miller, 2016; Aslam et al., 2019), immune evasion (Randolph-Habecker et al., 2002; Elder et al., 2019), and myeloid differentiation (Zhu et al., 2018; Crawford et al., 2019).

Analyses of murine, rat, guinea pig, and rhesus cytomegaloviruses are also yielding an understanding of the roles of CMV GPCRs in vivo (Beisser et al., 1998; Kaptein et al., 2003; Case et al., 2008; Alcendor et al., 2009; Cardin et al., 2009; Takeda et al., 2018; Frank et al., 2019). The HCMV GPCRs UL33 and UL78 are well conserved across mammalian species, but homologs of US27 and US28 are only found in primate CMVs, with five homologs of US28 in rhesus CMV (Alcendor et al., 2009). Thus, it is not straightforward to assess the conservation of function of the CMV GPCRs. For example, deletion of M33, the murine homolog of UL33, from mouse CMV (MCMV) produced a virus with...
an attenuated phenotype in vivo, with ablated salivary gland replication when using the intraperitoneal infection route and reduced dendritic cell trafficking after intranasal infection (Case et al., 2008; Farrell et al., 2011, 2018). Substitution of HCMV US28 for MCMV M33 could only partially restore aspects of both phenotypes, whereas HCMV UL33 could complement the salivary gland replication phenotype (Case et al., 2008; Farrell et al., 2011, 2018). It is therefore highly credible that US28 plays important roles in vivo processes such as viral dissemination, but the lack of tractable small-animal models of HCMV does not allow us to completely dissect the roles of each vGPCR in human host-specific viruses.

The KSHV vGPCR ORF74 has an important role in lytic replication. The promoter of ORF74 is likely responsive to the lytic switch protein called Replication and Transcription Activator (known as RTA). Depletion of ORF74 reduced viral titers in a reactivation setting in primary effusion lymphoma and endothelial cells (Chiu et al., 2002; Zhang et al., 2005; Chen et al., 2009; Sandford et al., 2009; López-Rodríguez et al., 2019). Furthermore, although ORF74 is dispensable for acute infection, deletion of ORF74 in MHV68 leads to a failure of reactivation during in vivo infection of mice (Moorman et al., 2003; López-Rodríguez et al., 2019). The constitutive signaling of ORF74 contributes to successful infection via both autocrine and paracrine mechanisms, for example, by sustained expression of replication and transcription activator via protein kinase C activation in lytically infected cells (Bottero et al., 2009), and maintenance of latent gene expression in bystander cells by cyclooxygenase 2 and prostaglandin E2 induction (Sharma-Walia et al., 2006; Shelby et al., 2007; Bottero et al., 2009). Further paracrine roles for ORF74 have been elucidated in the context of oncogenesis (discussed later in section III Role of Viral G Protein–Coupled Receptors in Disease). Nonetheless, it is not entirely clear what the consequences of, for example, increased angiogenic factor secretion might be in a nonlesion context. Additional studies using elegant tissue or animal models are needed to understand these phenomena.

Clearly, there is more to be understood about the vGPCRs during viral infections—perhaps no more so than for the HHV-6A/B and HHV-7 vGPCRs U12 and U51, for which only a little is known about their roles in latent or lytic viral life cycles. U51 is a positive regulator of HHV-6A replication that might be related to cell-cell spread and may induce leukocyte migration in response to chemokine gradients (Zhen et al., 2005; Catusse et al., 2008). Recently, the presence of HHV-6, and vGPCRs U12 and U51 mRNA, was detected in thyroid gland tissues of patients with autoimmune thyroiditis (AIT) (Sultanova et al., 2020). Moreover, CCL5 levels in blood plasma were lowered in patients with AIT in which U12 and U51 gene expression was detected, indicating a potential role for these vGPCRs in influencing CCL5 signaling in AIT. Otherwise, our knowledge of the functions of U12 and U51 is limited to chemokine binding and signaling, often known only in the context of exogenous expression of the receptors in isolation (Davis-Poynter et al., 1997; Isegawa et al., 1998; Menotti et al., 1999; Milne et al., 2000; Nakano et al., 2003; Tadagaki et al., 2005; Fitzsimons et al., 2006). Since vGPCRs dimerize and couple with host and viral proteins (described in section I Family of Viral G Protein–Coupled Receptors), a complete understanding of vGPCR function will likely require analyses of endogenous protein levels in the context of viral infection.

The EBV vGPCR BILF1 almost certainly contributes to immunomodulation and immune evasion in the infected host (Arfelt et al., 2015; Morales-Sánchez and Fuentes-Panana, 2018). Despite the absence of ligand binding activity, BILF1 reduces the levels of antiviral protein kinase R when expressed exogenously (Beisser et al., 2005). Further immunomodulatory roles for BILF1 have been proposed, including interference with CXCR4 signaling and upregulation of leukocyte adhesion molecule intercellular adhesion molecule 1 (ICAM1) expression (Nijmeijer et al., 2010; Guo et al., 2020). More widely characterized is the ability of BILF1 to downregulate cell-surface MHC class I molecule expression via a direct interaction between BILF1 and MHC molecules, leading to reduced T-cell recognition (Zuo et al., 2009, 2011; Griffin et al., 2013; Fares et al., 2019). Interestingly, mutations in the N terminus and third extracellular loop of BILF1 ablated MHC class I downregulation but not constitutive GPCR signaling (Fares et al., 2019). This suggests that there are further functions of BILF1 related to signaling that are yet to be elucidated. Like many other herpesviral immune modulators, there is no apparent requirement of BILF1 for lytic replication, perhaps indicating that BILF1 constitutive signaling does not play a significant role in activation of lytic viral gene expression (Zuo et al., 2011). Further studies, particularly making use of BILF1 deletions and mutations in the context of viral infection, are required to provide increased insight into its role in viral infection.

III. Role of Viral G Protein–Coupled Receptors in Disease

Infections with most herpesviruses are generally asymptomatic in healthy individuals. Nonetheless, these viruses can be opportunistic pathogens and take advantage when the immune system is compromised. Consequently, herpesvirus infections are associated with various diseases, including proliferative diseases, transplant-associated diseases, inflammatory diseases, and cardiovascular diseases. In view of the prominent role of human GPCRs in multiple (patho)physiologic
Fig. 2. Major signaling pathways activated by human herpesvirus–encoded GPCRs in different disease settings. (A) Overview of the different (proliferative) signaling pathways activated by US28 (yellow arrows), UL33 (dark yellow arrows), ORF74 (pink arrows), and BILF1 (blue arrows) in cancer cells. Activation of some of these pathways results in the activation of cyclooxygenase 2 (COX2) and secretion of IL-6, PGE2, and VEGF. Secreted IL-6 activates the IL-6 receptor [consisting of the IL-6 receptor subunit (IL6R) and glycoprotein 130 (gp130)]. Activation of the IL-6 receptor results in the stimulation of the Janus kinase 1 (JAK1)-STAT3 pathway, leading to a feed-forward loop. Activation of these pathways contributes to several cancer hallmarks, including sustained proliferative signaling, tissue invasion, angiogenesis, and immune evasion. (B) Binding of CCL5 to US28 activates several pathways that result in smooth muscle cell migration in cardiovascular diseases. CCL5-mediated activation of US28 stimulates the Rho-associated protein kinase (ROCK) pathway and the formation of Src-mediated focal adhesion kinase (FAK) complexes, resulting in cytoskeletal changes, cell detachment, and subsequent cell migration. (C) US28 suppresses the major...
processes and diseases, it is not surprising that herpesvirus-encoded GPCRs also play a key role in several of the processes underlying herpesvirus-associated diseases (Fig. 2).

**A. Proliferative Diseases**

The role of KSHV, EBV, and HCMV in different types of cancer has been a major point of discussion in the last decades. Although the role of KSHV and EBV in cancer development is clear, the role for HCMV in (certain) cancer types is less pronounced and is still being investigated. However, numerous studies have also shown, or suggested, an involvement of herpesvirus-encoded GPCRs in the initiation and/or progression of different types of cancer over the last couple of years (Mesri et al., 2010; Jha et al., 2016; Nauclér et al., 2019). In this paragraph, we will give a general overview of the effects of several vGPCRs in an oncological context. An in-depth analysis of the different signaling pathways activated by vGPCRs related to the cancer hallmarks has been provided recently (van Senten et al., 2020b). Although we will focus on the role of vGPCRs, it is important to note that these are not the only viral proteins that (may) contribute to cancer initiation and/or progression. Some other examples of viral proteins that are involved include latency-associated nuclear antigen (LANA), v-cyclin, and viral B-cell proteins that are involved in latency-associated and/or progression. Some other examples of viral proteins that (may) contribute to cancer initiation and, consequently, tumor initiation and maintenance (Pati et al., 2001; Montaner et al., 2004, 2006; Martin and Gutkind, 2009).

Ligand-independent signaling of ORF74 leads to the activation of multiple G protein signaling pathways, including phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) and extracellular signal-regulated kinase (MAPK1/ERK) pathways, resulting in the activation of several transcription factors, including NF-κB, NFAT, and HIF-1α (Sodhi et al., 2000; Shepard et al., 2001, Smit et al., 2002; Montaner et al., 2004; Shelby et al., 2007). As a result, ORF74 activates several oncogenic pathways, also promoting secretion of proliferative and proangiogenic paracrine factors such as VEGF, IL-6, and PGE2. Consequently, ORF74 can, for example, induce the transformation of endothelial cells (Bais et al., 2003). These results were further corroborated in vivo with transgenic ORF74-expressing mice developing KS-like lesions (Yang et al., 2000; Guo et al., 2003). Moreover, ORF74 activates YAP/TAZ, which are coactivators interacting with the transcriptional enhanced associate domain family of DNA-binding factors in a Go12/13-dependent manner, resulting in dysregulation of the Hippo-YAP/TAZ pathway, which promotes proliferation and migration in SVEC and HEK293A cells (Liu et al., 2015). The Hippo-YAP/TAZ signaling pathway plays an important role in organ growth and development, and dysregulation of this pathway is associated with cancer stem cells stemness (van Senten et al., 2020b). ORF74-mediated transformation and survival in SVEC cells was impaired upon treatment with verteporfin, a YAP inhibitor (Liu et al., 2015). Besides the constitutive signaling of ORF74, studies have shown that ligand-induced signaling of ORF74 can also play a role in tumorigenesis (Holst et al., 2001; Peng et al., 2010). Expression of ORF74
mutants unresponsive to agonist stimulation in transgenic mice resulted in a smaller fraction of mice developing KS-like lesions. These studies combined show the importance of both ligand-dependent and -independent signaling of ORF74 in tumorigenesis.

EBV has been implicated in multiple cancer types, including Burkitt lymphoma, (non-)Hodgkin lymphoma, epithelial cell tumors, gastric carcinoma, and nasopharyngeal carcinoma (Pearson, 1993; Thompson and Kurzrock, 2004; Fukayama, 2010). However, the precise role of EBV in Burkitt lymphoma remains not fully understood, as viral gene expression seems to be restricted in Burkitt lymphoma cells in primary tissues but not in culture conditions (Gregory et al., 1990). Interestingly, expression of EBV-encoded BILF1 has been detected at low levels in Burkitt lymphoma cell lines during latency as well as in EBV-transformed cell lines (Beisser et al., 2005; Quinn et al., 2014; Tierney et al., 2015). In vitro and in vivo experiments have shown that BILF1 expression induces tumorigenesis through constitutive signaling via Gαi, resulting in activation of cAMP response element (CRE)-mediated transcription (Beisser et al., 2005; Lyngaa et al., 2010). Although not apparent in relevant Burkitt lymphoma and lymphoblastoid B-cell lines, some studies have indicated activation of NF-κB–mediated signaling in COS-7 and HEK293T cells by BILF1 (Beisser et al., 2005; Paulsen et al., 2005; Spiess et al., 2015a).

As described in section II Viral G Protein–Coupled Receptors in a Viral Setting, BILF1 induces downregulation of MHC class I surface expression (Griffin et al., 2013). Downregulation of human leukocyte antigen (HLA) class molecules results in the modulation of antigen presentation to cytotoxic T cells and could be beneficial for immune evasion of EBV-infected cancer cells.

In addition, HCMV has also been associated with multiple cancers, including colon cancer, prostate cancer, breast cancer, and glioma (Cobbs et al., 2002; Harkins et al., 2002; Samanta et al., 2003; Mitchell et al., 2008; Michaelis et al., 2009; Baryawno et al., 2011). In particular, the link between HCMV and glioblastoma, the most common and aggressive form of malignant brain tumors, has been investigated extensively. The presence of HCMV is still debated, since multiple studies were able to detect HCMV nucleic acids and proteins in patient samples, whereas other studies were not (Dziurzynski et al., 2012). This could be explained by the use of distinct detection techniques associated with differences in detection sensitivity and handling of different cancer cell subtypes during divergent stages of tumor progression. Another explanation that has been proposed involves a “hit-and-run” mechanism whereby HCMV genes are transiently expressed to induce a transformed cellular state (Shen et al., 1997). Unlike EBV and KSHV, HCMV is generally believed to play an oncomodulatory role by enhancing progression of cancers, rather than being an oncogenic virus (Dziurzynski et al., 2012). However, a recent study did show that the clinical HCMV strain HCMV-DP was able to transform primary human mammary epithelial cells by dysregulation of telomerase, p53, and retinoblastoma protein (RB), resulting in the induction of tumor formation in vitro and in vivo (Kumar et al., 2018). These results imply that some strains of HCMV may be more oncogenic than others. Over the years, extensive research has been done on the effects of HCMV on the different hallmarks and stages of cancer. Interestingly, HCMV infection was found to result in the activation of many different oncogenic processes. HCMV can lead to survival of cancer stem cells; induction of DNA damage; induction of inflammatory cytokines (including CCL2, CCL3, CCL5, interferon-γ (IFN), tumor necrosis factor-α (TNF), IL-4, and IL-18); and expression of oncogenic pathways such as COX-2, NF-κB, and the STAT3-IL-6 pathway, promoting tumor initiation, chronic inflammation, angiogenesis, and proliferation (Shen et al., 1997; Fortunato and Spector, 1998, 2003; Maussang et al., 2009; Siew et al., 2009; Slinger et al., 2010; Soroceanu et al., 2015; Fornara et al., 2016; Liu et al., 2017; Clement and Humphreys, 2019). In addition, several studies have also shown an effect of HCMV on tumor invasiveness and aggressiveness by affecting mesenchymal-epithelial transition and epithelial-mesenchymal transition. In addition, immunomodulatory effects of HCMV, including promotion of M2 macrophage maturation, inhibition of dendritic cell maturation, and modulation of the activity of monocytes, have been reported (Cobbs et al., 2008; Dziurzynski et al., 2011; Fiallos et al., 2009; Avdic et al., 2016; Oberstein and Shenk, 2017; Teo et al., 2017; Moussawi et al., 2018). In a recent study using a murine glioblastoma model, MCMV reactivation was observed in glioblastoma cells and intratumoral pericytes, resulting in significant reduction in survival rate (as opposed to uninfected animals) (Krenzlin et al., 2019). This effect could be counteracted upon treatment of mice with the antiviral drug cidofovir, showing the oncomodulatory role of CMV in glioblastoma.

US28 is one of the HCMV-encoded vGPCRs that has been detected in patient material of HCMV-positive patients with cancer, including patients with colorectal cancer and glioblastoma (Slinger et al., 2010; Soroceanu et al., 2011; Cai et al., 2016; Heukers et al., 2018). Over the years, it has become clear that US28 plays a predominant role in the oncomodulatory behavior of
HCMV. In the last decade, extensive research has been performed on the role of US28 signaling in cancer (mostly glioblastoma). US28 constitutively activates, in a primarily Gαq-dependent manner, multiple onco-
genic pathways, including the NF-κB, NFAT, CREB, HIF-1α, STAT3, and TCF-LEF pathway (Maussang et al., 2009; Slinger et al., 2010; Langemeijer et al., 2012; de Wit et al., 2016). Activation of these transcription factors leads to the activation of cyclin D1 and cyclooxygenase 2, resulting in the secretion of PGE2, IL-6, and VEGF, inducing enhanced inflammation, proliferation, and angiogenesis. Although US28 ligand-independent signaling plays an important role, ligand-
dependent signaling is also of significance. Scavenging of CCL5 via CCL5-specific antibodies reduces US28-
enhanced invasiveness of primary glioblastoma cells (Soroceanu et al., 2011). Moreover, CCL5 enhances US28 signaling, resulting in enhanced β-catenin sign-
aling and phospholipase C activation (Langemeijer et al., 2012; Heukers et al., 2018). As multiple US28 ligands are expressed at high levels in, for example, glioblastoma, it is reasonable that ligand-dependent US28 signaling plays an important factor in the onco-
modulatory role of HCMV (Desbaillets et al., 1994). Via the activation of these oncogenic pathways, US28 expression led to enhanced tumor growth in vivo in different cancer models. In an orthotopic glioblastoma model, US28-expressing U251 glioblastoma tumors showed significant tumor expansion already at day 10 postsurgery, whereas this was only observed at day 40 for control U251 tumors (Heukers et al., 2018). More-
over, infection of U251 and primary glioblastoma cells with HCMV led to an increase in spheroid and neuro-
sphere size, which was not as apparent when cells were infected with an HCMV mutant devoid of US28. Furthermore, in a colitis-tumor model, transgenic mice that expressed US28 in intestinal epithelial cells dis-
played a higher tumor burden compared with control mice (Bongers et al., 2010). Moreover, coexpression of CCL2 resulted in enhanced tumorigenesis, suggesting a potential direct interaction between CCL2 and US28 signaling in this model. Finally, G protein–dependent US28 signaling does not seem to be solely responsible for enhanced tumor growth. Using a xenograft model, NIH-3T3 cells stably expressing a G protein–uncoupled US28 mutant (US28 R129A/R256A) still showed US28-
enhanced tumor growth, although not to such an extent as NIH-3T3 cells expressing US28 and wild-type re-
ceptor (Maussang et al., 2006).

Besides US28, an oncomodulatory role for the other HCMV-encoded GPCR UL33 has also been recently described (van Senten et al., 2019). Similar to US28, UL33 activates multiple signaling pathways, result-
ing in NFAT-, CREB-, HIF-1α–, STAT3–, and TCF-
LEF–mediated transcription. Strikingly, UL33 signaling did not activate the NF-κB pathway, in contrast to US28. Similar to US28, UL33 signaling resulted in enhanced IL-6 secretion in glioblastoma cells and resulted in enhanced three-dimensional tumor spheroid growth. Using an orthotopic glioblastoma model simi-
lar to before, UL33 expression in glioblastoma cells also resulted in enhanced tumor growth, albeit with a delayed onset compared with US28. In HCMV-
infected glioblastoma cells, differences in spatiotempo-
ral expression of both receptors was observed, making it plausible that the receptors complement each other when rewiring cellular signaling of the infected cells in a cancer setting. Overall, similar to US28 (but less pronounced), the constitutive activity of HCMV-encoded UL33 is able to activate oncogenic pathways and enhance tumor growth.

B. Cardiovascular Diseases

HCMV infection has also been associated with the development of vascular diseases such as atherosclero-
sis, which is an underlying cause of acute myocardial infarction (Melnick et al., 1996). Although the specific role of HCMV and vascular diseases is still being debated, HCMV seropositivity has been associated with artery diseases, and HCMV nucleic acids and antigens have been detected in vessels of patients (Melnick et al., 1983; Horváth et al., 2000). Moreover, HCMV is known to infect cell types such as macrophages, smooth muscle cells, and endothelial cells, which play an important role in cardiovascular diseases (Caposio et al., 2011). Over the past years, the Streblow laboratory has shown that US28 signaling mediates migration of these types of cells, which is an impor-
tant underlying factor in cardiovascular diseases (Streblow et al., 1999, 2003; Melnychuk et al., 2004; Vomaske et al., 2009). Interestingly, ligand-dependent US28 signaling and cellular backgrounds play key roles in cell migration. For example, CCL5 binding to US28 promotes smooth muscle cell migration via coupling of Gα12/13, resulting in activation of the Src-
focal adhesion kinase signaling pathway. However, CX3CL1 binding to US28 inhibits CCL5-mediated smooth muscle cell migration (Streblow et al., 1999, 2003; Melnychuk et al., 2004; Vomaske et al., 2009). In contrast, CX3CL1 induces US28-mediated mac-
rophage migration in a Gαq-dependent manner, whereas this is inhibited by CCL5 binding to the receptor (Vomaske et al., 2009; Hjortø et al., 2013). Taken together, these results show that HCMV and US28 can result in infiltration of smooth muscle cells in the vessel intima, resulting in narrowing of the vessels, and infiltration of HCMV-infected mono-
cytes and macrophages into atherosclerotic lesions. Finally, HCMV-infected endothelial cells also show an increase of secreted cytokines and growth factors (in-
cluding IL-6 and VEGF) involved in angiogenesis and wound healing (Dumortier et al., 2008). As US28 signaling induces IL-6 and VEGF secretion, it could play an important role in the enhanced secretion of
further exciting insight about the roles of individual vGPCRs function in vivo. However, the species-specific nature of herpesviruses will continue to create challenges in understanding how vGPCRs function in vivo.

Other types of evidence for a role of vGPCRs in transplant-associated disease can also be considered. Observational studies have found US28 antigen or transcript present in renal allografts and in the blood of post-transplant patients (Boomker et al., 2006; Holtappels et al., 2020; Shah et al., 2020). As described in section II Viral G Protein–Coupled Receptors in a Viral Setting, US28 and homologs are heavily implicated in in vivo dissemination processes that could be important for the systemic disease often seen post-transplant. US28 also contributes to viral spread in epithelial cells and vascular smooth muscle cells in vitro, which could have particular relevance for solid organ transplantation (Noriega et al., 2014; Lollinga et al., 2017). Finally, US28 plays an important role in the latency of human cytomegalovirus (Humby and O’Connor, 2015; Krishna et al., 2020; Holtappels et al., 2020; Shah et al., 2020). However, the species-specific nature of herpesviruses will continue to create challenges in understanding how vGPCRs function in vivo.

C. Post-transplant Disease

Viral GPCRs contribute to important in vivo processes such as viral dissemination, latency and reactivation, and immune evasion (described in section II Viral G Protein–Coupled Receptors in a Viral Setting). During solid organ or hematopoietic stem cell transplantation (HSCT), immunosuppressive regimes combined with inflammation commonly lead to systemic reactivation of herpesviruses (Haidar and Singh, 2017; Hill et al., 2017). HCMV reactivation from latency causes disease depending on the nature of the graft (HSCT, solid organ) and the serostatus of both the donor and recipient, whereas the source of the reactivation may come from either party (Ramanan and Razonable, 2013; Stern et al., 2019). The complex interplay between virus and host during transplantation is not fully dissected, although animal models have already shown that HCMV-encoded GPCRs contribute to post-transplant disease. Deletion of Rat CMV R33 reduced vascular sclerosis and increased time to chronic rejection in a rat model of heart transplantation, and deletion of MCMV M33 reduced cardiac allograft vasculopathy in a mouse model of aortic transplantation (Streblow et al., 2005; Fritz et al., 2018). These animal models continue to be developed, including the generation of a humanized mice model, which may soon lead to further exciting insight about the roles of individual viral genes in post-transplant cytomegalovirus disease (Streblow et al., 2015; Crawford et al., 2020; Gezinir et al., 2020; Holtappels et al., 2020; Shah et al., 2020).

These factors found in HCMV-infected endothelial cells (Maussang et al., 2009).

TABLE 2 Overview of US28-targeting and modulating agents

<table>
<thead>
<tr>
<th>Molecule Class</th>
<th>Molecule Name/Scaffold</th>
<th>Mode of Action</th>
<th>Infection State</th>
<th>Functional Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small molecule</td>
<td>Piperazinylbenzothiepins; cinchonidine derivatives; arylamines; benzamides</td>
<td>Antagonists</td>
<td>—</td>
<td>Ligand blocking</td>
<td>Vischer et al. (2014)</td>
</tr>
<tr>
<td>Methiothepin; Octoclotoxin; S(-)-Iodobenzamide</td>
<td>—</td>
<td>In vitro</td>
<td>Ligand blocking and partial inhibition of US28 constitutive activity</td>
<td>Vischer et al. (2010)</td>
<td></td>
</tr>
<tr>
<td>VUF2274</td>
<td>Antagonist/full inverse agonist</td>
<td>Latent infection</td>
<td>In vitro</td>
<td>Full reactivation of latently infected cells resulting in T-cell–mediated cell death</td>
<td>Casarosa et al. (2003b); Krishna et al. (2017a)</td>
</tr>
<tr>
<td>Derivatives of flavonoids; biphenyl amides; CX3CR1 antagonists; VUF2274</td>
<td>—</td>
<td>In vitro</td>
<td>Ligand blocking and enhanced US28 signaling/partial inhibition of US28 constitutive activity</td>
<td>Kralj et al. (2011), (2013); Luckmann et al. (2017); Amàrândi et al. (2018)</td>
<td></td>
</tr>
<tr>
<td>VUN100-PS</td>
<td>Antagonist/photonsensitizer-induced cell death</td>
<td>Cancer setting</td>
<td>In vitro</td>
<td>Selective killing of US28-expressing glioblastoma cells</td>
<td>De Groof et al. (2019b)</td>
</tr>
<tr>
<td>Toxin-coupled chemokine</td>
<td>F49A-FTP</td>
<td>Toxin-induced cell death</td>
<td>Lytic infection</td>
<td>Selective killing of HCMV-infected cells</td>
<td>Spiess et al. (2015b)</td>
</tr>
</tbody>
</table>

| — | Casarosa et al. (2003b); Krishna et al. (2017a) |
| — | Kralj et al. (2011), (2013); Luckmann et al. (2017); Amàrândi et al. (2018) |
| — | De Groof et al. (2019b) |
| — | Spiess et al. (2015b) |
(Krishna et al., 2018; Elder and Sinclair, 2019). Furthermore, US28 influences myelopoiesis and myeloid differentiation (Zhu et al., 2018; Crawford et al., 2019), which could potentially contribute to the well-established myelosuppression caused by HCMV in vitro (Rakusan et al., 1989; Sing and Ruscetti, 1990; Maciejewski and St Jeor, 1999; Mason et al., 2012; Hancock et al., 2020) and thus to the defects in engraftment observed in the clinic during HSCT (Sing and Ruscetti, 1995; Stern et al., 2019). As US28 is likely to be an important player in post-transplant events, the targeting of US28 is of great interest as a strategy to reduce the burden of CMV disease in this disease setting.

IV. Viral G Protein–Coupled Receptor–Targeting Modulators and Therapeutics

Although the studies described above revealed important roles for different viral GPCRs in various pathologies, agents modulating the activity of viral GPCRs have so far only been described for the HCMV-encoded US28 (Table 2). These inhibitors include both small molecules and antibody fragments. Based on their mode of action, these can be divided into neutral antagonists (i.e., blocking US28 ligand binding) or inverse agonists (i.e., blocking US28 ligand binding and inhibiting the constitutive activity). In addition, chemokine-derived fusion proteins have been developed for targeted therapy of HCMV-infected cells. Some of these different US28-targeting agents have been used to target HCMV-infected cells in latent infection and in cancer models and will be described more in detail below.

A. Small Molecules

In the beginning of this century, multiple different chemical scaffolds (benzamides, cinchonine and derivatives, arylamines, and piperezimidobenzothiepins) were patented for their ability to act as US28 antagonists in in vitro signaling assays (Vischer et al., 2014). Some of these drugs, including methiothepin and octoclothepin, inhibited US28 ligand binding and partially inhibited the constitutive activity of US28 (Vischer et al., 2010).

Besides these scaffolds, other small molecules were also described in literature. One interesting example is VUF2274, which was identified as a full inverse agonist (Casarosa et al., 2003b). VUF2274, derived from a CCR1 antagonist scaffold, inhibited chemokine binding and was the first molecule to inhibit the constitutive activity of US28 with micromolar potency. Moreover, US28 has been described as a coreceptor for HIV-1 entry. VUF2274 could partially inhibit this US28-mediated HIV-1 entry. In later studies, VUF2274 was used to establish the essential role of US28 in the HCMV latency (Krishna et al., 2017a). Treatment of latently infected CD14+ monocytes with VUF2274 resulted in full reactivation of HCMV in these cells. Moreover, VUF2274 treatment drove recognition and killing of the reactivated monocytes by HCMV-specific T cells isolated from HCMV-positive donors.

In more recent years, other groups have generated other small molecules against US28, which are based on either flavonoids, biphenyl amides, CX3CR1 antagonists, or the VUF2274 as scaffold (Kralj et al., 2011, 2013, 2014; Lückmann et al., 2017; Amàrandi et al., 2018). This new panel of molecules acted as agonists, antagonists, or inverse agonists depending on the cell type. Although multiple small molecules against US28 have been identified, most of these compounds were unsuitable for a clinical application without further improvements. Some have affinities and potencies in the micromolar range, whereas others were shown to be cytotoxic and/or showed crossreactivity toward other GPCRs, making them poor candidates for in vivo testing and subsequent clinical development. However, the availability of these compounds, in combination with the structural information from the crystal structure of US28 in complex with CX3CL1, provides a strong basis for the development of more and/or improved small molecules against US28 (Burg et al., 2015).

B. Toxin-Coupled Chemokines

The binding of chemokines to their cognate receptors can be exploited for the targeted delivery of effector molecules. For example, toxins can be redirected to cells of interest via fusion to targeting molecules (Allahyari et al., 2017). Upon binding, the fusion toxin protein (FTP) is internalized, and the toxin is processed and activated within the cell. Because of this mechanism of action, toxin-induced cell death can occur only upon proper uptake and processing of the FTP. Popular examples of toxins used for FTPs include bacterial toxins like Pseudomonas exotoxin A (PE38) and diphtheria toxin and plant toxins like ricin (Allahyari et al., 2017). In most cases, these molecules are targeted via antibody fragments binding to receptors or markers that are (over)expressed on the target cell, classifying them as immunotoxins.

Recently, PE38 was also fused to chemokines to target the toxin to US28-expressing cells (Spiess et al., 2015b, 2017; Krishna et al., 2017b). US28 is known to bind multiple chemokines, and interestingly, CX3CL1 binds US28 with a higher affinity than the native host receptor CX3CR1 (Casarosa et al., 2005). Based on this, the soluble part of CX3CL1 was used as a scaffold to design a mutant with even more enhanced selectivity toward US28 (Spiess et al., 2015b). Fusion of PE38 to this CX3CL1 mutant resulted in killing of lytically infected cells and antiviral activity in infected humanized mice (Spiess et al., 2015b). In follow-up studies, CX3CL1-based FTP was able to specifically kill latently infected cells, suggesting that the HCMV latent...
reservoir could be cleared with the fusion toxin protein (Krishna et al., 2017b).

Despite these promising results, there are some challenges to be taken into account. Serial passage of HCMV resulted in the development of resistance mutants with a truncated US28 (having a premature stop codon in the extracellular loop 3). This results in reduced surface expression of US28, lowering the number of entry points for FTPs (Spiess et al., 2015b). Moreover, FTPs are known to be highly immunogenic, which hampers clinical development because of the risk of developing anti-drug antibodies (Allahyari et al., 2017). Finally, despite a slightly higher selectivity toward US28, the CX3CL1-based fusion toxin protein still binds to CX3CR1. This could lead to off-target effects at higher concentrations in vivo. However, ex vivo treatment, using normothermic perfusion, of HCMV-positive organs prior to transplantation could negate these problems (Vp Ribeiro et al., 2020).

C. Viral G Protein–Coupled Receptor–Targeting Nanobodies

As an alternative to the small molecules, more recent research has been focusing on finding GPCR-targeting antibodies and fragments thereof. In particular, nanobodies (antibody fragments derived from the heavy chain—only antibodies of camelids) have gained a lot of interest because of their ability to recognize and stabilize the nonlinear, conformational epitopes typically found of GPCRs (De Groof et al., 2019a; Heukers et al., 2019). These characteristics have been instrumental for the generation of GPCR crystals, thereby allowing the reconstruction of GPCR structures. The first structures of GPCRs stabilized by intracellularly binding nanobodies were reported by Kobilka and Steyaert and colleagues for the β2-adrenergic receptor (Rasmussen et al., 2011). We have shown that nanobodies can also specifically bind the extracellular side of GPCRs—namely, CXCR4 and ACKR3 (also known as CXCR7)—and modulate their function in vitro and in vivo (Jähnichen et al., 2010; Maussang et al., 2013). GPCR-targeting nanobodies are interesting modalities to image, stabilize, and modulate GPCRs, as they can be easily formatted and target GPCRs from either the extracellular side or the intracellular side (De Groof et al., 2019a; Heukers et al., 2019).

In 2018, we generated a US28-targeting nanobody (US28-Nb) by immunizing a llama and an alpaca with DNA encoding this GPCR, followed by US28-expressing cells (Heukers et al., 2018). Pharmacological characterization of the US28-Nb showed that the nanobody was able to displace US28 ligands with sub-micromolar affinity. Genetically coupling two of these US28-Nbs through a long flexible glycine-serine linker, generating a bivalent US28-Nb, resulted in a 100-fold increase in apparent binding affinity and potency (low nanomolar range) through avid binding. Moreover, as previously observed for the CXCR4 and ACKR3 nanobodies, this also resulted in partial inverse agonistic properties. The bivalent US28-Nb was able to inhibit US28 constitutive activity up to 50%. As a consequence, this bivalent molecule was able to impair US28-mediated glioblastoma tumor growth both in vitro and in vivo.

In a follow-up study, and to find more potent candidates, new US28-targeting nanobodies were generated through new immunizations and phage panning (De Groof et al., 2019b). One lead nanobody, termed VUN100, bound to a similar epitope on the extracellular domains of US28 as the previous US28-Nb. VUN100 also acted as an antagonist by competing with CCL5 and CX3CL1 for binding to US28, but with a 170-fold increase in potency as compared with the previous nanobody. Having a US28-targeting nanobody with nanomolar affinity enabled us to use this nanobody for targeted therapy approaches. By introducing a C-terminal cysteine to the nanobody, the photosensitizer IRDye700DX was directionally conjugated to VUN100. Treatment of US28-expressing glioblastoma cells and subsequent illumination of the nanobody-photosensitizer conjugate with near-infrared light resulted in specific killing of US28-expressing two-dimensional and three-dimensional in vitro cultures.

V. Concluding Remarks and Future Perspectives

The relevance of viral GPCRs in the viral life cycle and herpesvirus-associated diseases has become clear over the last decade. However, there are still some unanswered questions that remain to be addressed.

A. Pharmacological Characterization of Viral G Protein–Coupled Receptors

From a pharmacological point of view, we have been able to elucidate multiple aspects of several of these vGPCRs. However, some of these vGPCRs are still designated as orphan GPCRs. As such, it would be interesting to further explore which potential ligands bind these receptors. To date, only chemokines have been identified as ligands for these vGPCRs. However, it is not unlikely that other classes of ligands can bind to these receptors. It has, for example, been proposed that US28-mediated establishment and maintenance of latency could be driven by an unknown US28 ligand that binds differently to US28 as compared with the known (chemokine) ligands (Krishna et al., 2019). Moreover, nonchemokine ligands, such as macrophage migration inhibitory factor (MIF), have already been shown to bind to human chemokine receptors such as CXCR2 and CXCR4 (Weber et al., 2008; Kraemer et al., 2011; Rajasekaran et al., 2016). Performing (high-throughput) ligand binding screening assays using bioluminescence resonance energy transfer (BRET) or fluorescence resonance energy transfer (FRET) technology
could unveil novel ligands binding to these vGPCRs, which could lead to more insight into receptor function.

In addition, not much is known about the signaling pathways or the influence on cellular signaling of some of these receptors. In particular, limited information is available on the signaling properties of HCMV-encoded US27 and UL78, HHV-6–encoded U12, and HHV-7–encoded U12 and U51. It is unlikely, from an evolutionary point of view, that these herpesviruses contain genes encoding for nonfunctional vGPCRs. As such, further investigation into the signaling properties of the vGPCRs, their ability to form dimers with GPCRs of the host, or scavenging of ligands and thereby influencing cellular signaling would be interesting to pursue. Currently, most studies have focused on G proteins and G protein–mediated signaling. However, GPCRs can also signal in a G protein–independent manner (Gurevich and Gurevich, 2019). This can include signaling via arrestins or G protein-coupled receptor kinases (GRK). Moreover, GPCRs can interact with proteins via PDZ-binding motifs regulating GPCR signaling and localization (Dunn and Ferguson, 2015). Further investigation of signaling via different G protein–independent signaling pathways through PDZ-binding motifs (and associated PDZ domain–containing proteins) or other vGPCR-interacting proteins could provide new insight into the signaling properties of one or more vGPCRs. Moreover, it would be interesting to investigate the interactome of vGPCRs in different cell types, as it has become clear that the cellular context is an important factor when studying vGPCR signaling. Finally, the various studies that investigated vGPCR signaling focused on vGPCRs in isolation. An important step is to monitor the effects of vGPCR signaling on cellular signaling in a viral setting, since the influence of other vGPCRs or other viral proteins should be taken into account.

B. In Vivo Model Systems

To date, some of the roles of vGPCRs in the viral life cycle and disease settings have been elucidated via in vitro experiments. However, translating this to a more relevant in vivo setting remains challenging due to host tropism. Further research into novel transgenic herpesvirus strains or novel in vivo models could prove to be useful in gaining more insight into herpesviruses and validation of potential antivirals. To this end, humanized mouse models, which have been described above, seem to be a very interesting, although technically challenging, approach that could bridge the gap between the current in vitro experiments and clinical research.

C. Therapeutic Targeting of Viral G Protein–Coupled Receptors

Despite the limited information on the role of vGPCRs in vivo, it has become clear that these receptors could serve as a promising drug target in several disease settings. To date, this has resulted in the identification of several classes of US28-targeting molecules. For the other vGPCRs, no molecules against these receptors have been reported to our knowledge. However, several studies have shown that multiple chemokines have agonistic or inverse agonistic properties on ORF74 signaling (Geras-Raaka et al., 1998; Rosenkilde et al., 1999). Moreover, one of these studies shows that Zn2+ ions have inverse agonistic effects on an ORF74 mutant receptor in which histidine residues have been introduced, suggesting that nonpeptidic inverse agonists could be designed (Rosenkilde et al., 1999). Overall, these studies show that ORF74-targeting molecules could be designed. Moreover, other vGPCR-targeting molecules would be valuable tools and are potential therapeutics to identify and develop.

1. US28-Targeting Therapeutics

To date, several small molecules targeting US28 have been reported. However, selectivity, potency, or toxicity of the existing compounds needs to be improved before these compounds could proceed further into clinical studies. As such, optimizing the current compounds or investigating novel small-molecule scaffolds could result in finding more favorable US28-targeting small molecules. In the last couple of years, the Garcia group has gained notable insight in structural features and conformations of US28, which could provide essential information for the development of small molecules with improved affinities (Burg et al., 2015; Miles et al., 2018).

The CX3CL1-based fusion toxin protein has also shown great promise in clearing the HCMV latent pool via targeting of US28. Normothermic perfusion of HCMV-positive organs such as kidneys or lungs with the CX3CL1-based fusion toxin protein could prove to be one of the ways to clear HCMV-infected cells from rejected organs and reduce the waiting list for organ transplantations. One major problem moving forward could be the limited selectivity toward US28, since the CX3CL1-based fusion toxin protein still binds, albeit with low affinity, to the CX3CR1 receptor. This could be resolved by looking into new CX3CL1 mutants that show enhanced selectivity toward US28. Another option would be to conjugate these toxic groups to the US28-targeting nanobodies, which do not show any binding toward CX3CR1.

The functionalization of the US28-targeting nanobodies (using photosensitizers) has already shown its potential. However, the potency of this type of therapy needs to be validated in a viral and potentially in vivo setting. Recently, a glioblastoma mouse model using MCMV was used to investigate the role of CMV and glioblastoma (Krenzlin et al., 2019). Potentially, a chimeric MCMV strain in which M33 is replaced by US28 could be used in this setup to validate the potential of US28-targeted photodynamic therapy to clear glioblastoma cells (Farrell et al., 2018). However, it is important...
to note that other functional groups could be conjugated to such nanobodies instead. Some well known examples of cytotoxic domains used in targeted therapies are radioactive isotopes and toxins (De Groof et al., 2019a). In addition, US28 nanobodies could be used to redirect cytotoxic immune cells via coupling to T-cell or natural killer cell engagers or a chimeric antigen receptor T cells (CAR-T) approach, whereby T cells are engineered to express the US28 nanobodies as part of the chimeric antigen receptors and are activated upon binding of US28-expressing cells (Rozan et al., 2013; Dong et al., 2016; Li et al., 2018). Moreover, functionalized US28 nanobodies not only could be used in targeted cancer therapy but also could be of great interest in a cardiovascular or post-transplant disease setting.

Finally, bivalent formats of the US28-targeting nanobodies have inverse agonistic properties, which could be interesting for the clearance of the HCMV latent pool. Inhibiting the US28 constitutive activity using the full inverse agonist VUF2274 has already shown to fully reactivate latently infected cells. However, it would be interesting to investigate the effect of partial inverse agonistic US28-targeting nanobodies on HCMV reactivation.

2. Other Viral G Protein–Coupled Receptors as Drug Targets. Although research has mostly been focusing on finding US28-targeting therapeutics, targeting of other vGPCRs in specific disease settings would be an interesting approach. As such, modulators (small molecules, peptides, nanobodies, antibodies) targeting these vGPCRs are attractive, although none have been reported yet. Identification of modulators against the other vGPCRs would be important tools to further investigate the roles of these receptors in specific disease settings.

Besides modulating the receptor activity, these vGPCRs could also be used for targeted (cancer) therapy using similar approaches used for US28-targeted therapies. As such, finding (functionalized) nanobodies or toxin-coupled chemokine mutants targeting these vGPCRs could be envisioned. For instance, ORF74, BILF1, and UL33 are expressed on different types of cancer cells, making them appealing for targeted cancer therapy. Besides cancer treatment, other vGPCRs could also be interesting for the clearance of the latent pool via targeted therapy. In the case of HCMV, UL78 and UL33 are also potentially expressed in latently infected cells and could be useful additional targets. Moreover, BILF1 and ORF74 are also expressed during latency, but only at low levels. As expression levels are an important parameter for successful targeted therapy, it remains to be seen whether these expression levels are adequate.

Taken together, vGPCRs can be considered as attractive drug targets, as they redirect cellular signaling and significantly contribute and/or exacerbate proliferative, cardiovascular, and post-transplant diseases. Moreover, they play a prominent role in latency and immune evasion, thus escaping immune surveillance vital for the persistence of herpesviruses. Hence, modulators targeting vGPCRs are essential to further delineate their impact on disease progression and can be regarded as promising therapeutics for antiviral, cancer, and/or cardiovascular disease treatment.

Authorship Contributions
Wrote or contributed to the writing of the manuscript: De Groof, Elder, Siderius, Heukers, Sinclair, Smit.

References
Beisser PS, Verzijl D, Gruijthuijsen YK, Beuken E, Smit MJ, Leurs R, Bruggeman CA (1998) Identification of functionalized US28–targeting nanobodies as part of the chimeric antigen receptor–killer cell engagers or a chimeric antigen receptor–T cells cytotoxic immune cells via coupling to T-cell or natural killer cell engagers or a chimeric antigen receptor T cells (CAR-T) approach, whereby T cells are engineered to express the US28 nanobodies as part of the chimeric antigen receptors and are activated upon binding of US28-expressing cells (Rozan et al., 2013; Dong et al., 2016; Li et al., 2018). Moreover, functionalized US28 nanobodies not only could be used in targeted cancer therapy but also could be of great interest in a cardiovascular or post-transplant disease setting.

Finally, bivalent formats of the US28-targeting nanobodies have inverse agonistic properties, which could be interesting for the clearance of the HCMV latent pool. Inhibiting the US28 constitutive activity using the full inverse agonist VUF2274 has already shown to fully reactivate latently infected cells. However, it would be interesting to investigate the effect of partial inverse agonistic US28-targeting nanobodies on HCMV reactivation.

2. Other Viral G Protein–Coupled Receptors as Drug Targets. Although research has mostly been focusing on finding US28-targeting therapeutics, targeting of other vGPCRs in specific disease settings would be an interesting approach. As such, modulators (small molecules, peptides, nanobodies, antibodies) targeting these vGPCRs are attractive, although none have been reported yet. Identification of modulators against the other vGPCRs would be important tools to further investigate the roles of these receptors in specific disease settings.

Besides modulating the receptor activity, these vGPCRs could also be used for targeted (cancer) therapy using similar approaches used for US28-targeted therapies. As such, finding (functionalized) nanobodies or toxin-coupled chemokine mutants targeting these vGPCRs could be envisioned. For instance, ORF74, BILF1, and UL33 are expressed on different types of cancer cells, making them appealing for targeted cancer therapy. Besides cancer treatment, other vGPCRs could also be interesting for the clearance of the latent pool via targeted therapy. In the case of HCMV, UL78 and UL33 are also potentially expressed in latently infected cells and could be useful additional targets. Moreover, BILF1 and ORF74 are also expressed during latency, but only at low levels. As expression levels are an important parameter for successful targeted therapy, it remains to be seen whether these expression levels are adequate.

Taken together, vGPCRs can be considered as attractive drug targets, as they redirect cellular signaling and significantly contribute and/or exacerbate proliferative, cardiovascular, and post-transplant diseases. Moreover, they play a prominent role in latency and immune evasion, thus escaping immune surveillance vital for the persistence of herpesviruses. Hence, modulators targeting vGPCRs are essential to further delineate their impact on disease progression and can be regarded as promising therapeutics for antiviral, cancer, and/or cardiovascular disease treatment.

References


Influenza A virus (IAV) infection is a major cause of respiratory tract infections, leading to significant morbidity and mortality. The virus infects the respiratory mucosa, where it replicates and spreads to the airways and lungs, causing symptoms ranging from mild cold-like illnesses to severe pneumonia. The symptoms of IAV infection are primarily due to the actions of viral hemagglutinin (HA) and neuraminidase (NA) proteins, which mediate virus attachment, entry, and release from infected cells, respectively.

Hemagglutinin (HA) is a surface glycoprotein that binds to specific sialic acid receptors on the host cell surface, facilitating viral entry. Neuraminidase (NA) is an enzyme that cleaves sialic acids from cell surface glycans, enabling virus release and particle shedding.

The HA and NA proteins are highly variable, allowing IAV to evade host immune responses through antigenic drift and antigenic shift. Antigenic drift occurs through point mutations in the HA and NA genes, leading to small changes in the surface proteins that escape host immunity. Antigenic shift occurs through reassortment of the HA and NA genes between different IAV strains, resulting in the emergence of novel viruses with new antigenic properties.

The influenza virus is classified into three types: A, B, and C. Influenza A viruses are further divided into subtypes based on the HA and NA proteins they express. The HA proteins are divided into subtypes: H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, and H15. The NA proteins are divided into subtypes: N1, N2, N3, N4, N5, N6, N7, N8, N9, N10, N11, N12, N13, N14, and N15.

The most recent pandemic influenza A virus, the H1N1pdm09 strain, emerged in 2009 and caused a global pandemic. This strain was highly infectious and spread rapidly, infecting millions of people worldwide. The H1N1pdm09 strain is a reassortant virus, created through reassortment of HA and NA genes from different IAV strains.

Influenza A viruses can cause both mild and severe disease. Mild, self-limiting influenza is characterized by symptoms such as fever, cough, and fatigue. Severe, pandemic influenza can result in respiratory failure, ICU admission, and death. The severity of illness is influenced by factors such as age, underlying health conditions, and immune status.

Influenza A viruses can be transmitted through respiratory droplets, direct contact with infected respiratory secretions, and contact with contaminated surfaces. The virus is highly contagious, with an estimated R0 value of 1.2 to 3.5, meaning that each infected person can transmit the virus to 1.2 to 3.5 other people on average. Transmission is most efficient in close quarters such as households and schools.

Influenza A viruses are a significant threat to global public health, particularly during influenza pandemics. The virus is highly adaptable and can rapidly evolve, making the development of effective vaccines and antiviral therapies a priority. The influenza virus is a constantly changing threat, requiring ongoing surveillance and response efforts to protect public health.

This summary highlights the key aspects of influenza A virus infection, including the role of HA and NA proteins, the classification of influenza viruses, the epidemiology of the H1N1pdm09 pandemic, and the public health implications of influenza A virus infection. Further research is needed to better understand the virus and develop effective strategies to control its spread.


